- Home
- EOS vs XNCR Comparison
EOS vs XNCR Comparison
Compare EOS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EOS | XNCR |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | EOS | XNCR |
|---|---|---|
| Price | $22.97 | $18.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $23.20 |
| AVG Volume (30 Days) | 84.1K | ★ 758.3K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $150,132,000.00 |
| Revenue This Year | N/A | $22.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $15.62 | $6.92 |
| 52 Week High | $20.63 | $27.24 |
Technical Indicators
Market Signals| Indicator | EOS | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 50.67 | 68.18 |
| Support Level | $22.74 | $15.69 |
| Resistance Level | $23.05 | $17.83 |
| Average True Range (ATR) | 0.39 | 1.01 |
| MACD | 0.10 | 0.10 |
| Stochastic Oscillator | 93.95 | 91.72 |
Price Performance
Historical ComparisonAbout EOS Eaton Vance Enhance Equity Income Fund II
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.